Literature DB >> 2496047

Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.

I J Fidler1, D Fan, Y Ichinose.   

Abstract

Mouse alveolar macrophages (AM) were rendered tumoricidal after the intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE), a lipophilic derivative of muramyl dipeptide. The addition of recombinant mouse interferon gamma (r-IFN-gamma) to the liposomes significantly potentiated this effect. This potentiation was also observed in therapeutic studies of mice bearing well-established spontaneous lung melanoma metastases. Multiple intravenous injections of liposomes containing both MTP-PE and r-IFN-gamma resulted in 70% survival in one group treated for small lung metastases and 50% in another group treated for large lung metastases. These data demonstrate that the presentation of r-IFN-gamma and MTP-PE in liposomes is more efficient in inducing the destruction of metastases than either agent administered alone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2496047

Source DB:  PubMed          Journal:  Invasion Metastasis        ISSN: 0251-1789


  9 in total

Review 1.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

Review 2.  Mifamurtide for the treatment of nonmetastatic osteosarcoma.

Authors:  Kosei Ando; Kanji Mori; Nedège Corradini; Françoise Redini; Dominique Heymann
Journal:  Expert Opin Pharmacother       Date:  2011-02       Impact factor: 3.889

Review 3.  Therapy of disseminated melanoma by liposome-activated macrophages.

Authors:  I J Fidler
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 4.  Macrophages and cancer.

Authors:  P W Whitworth; C C Pak; J Esgro; E S Kleinerman; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1990-02       Impact factor: 9.264

5.  Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.

Authors:  B P Barna; M J Thomassen; M Maier; S V Medendorp; R R Tubbs; T Chiang; P Zhou; B Yen-Lieberman; S Singh-Burgess; S D Deodhar
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

6.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

7.  In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362.

Authors:  T Utsugi; C P Dinney; J J Killion; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.

Authors:  T Utsugi; A Nii; D Fan; C C Pak; Y Denkins; P van Hoogevest; I J Fidler
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.